Selected 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors. A look into their use and potential in pre-diabetes and type 2 diabetes Cover

.blurhash-client-img { display: none !important; }

Selected 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors. A look into their use and potential in pre-diabetes and type 2 diabetes

Endocrine Regulations

Volume 55 (2021): Issue 3 (July 2021)

By: Douglas Edward Barre and Kazimiera Amelia Mizier-Barre

Open Access

|Sep 2021

Authors

Douglas Edward Barre

ed_barre@cbu.ca

Department of Health Sciences, Cape Breton University, Canada

Kazimiera Amelia Mizier-Barre

Department of Health Sciences, Cape Breton University, Canada

DOI: https://doi.org/10.2478/enr-2021-0020 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668

Journal RSS Feed

Language: English

Page range: 182 - 192

Published on: Sep 13, 2021

Published by: Slovak Academy of Sciences, Institute of Experimental Endocrinology

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

flaxseed lignan complex,

cinnamic acids,

3-hydroxy-3-methylglutaric acid,

3-hydroxy-3-methylglutaric acid coenzyme A reductase inhibition,

type 2 diabetes mellitus,

central obesity,

pro-thrombosis,

oxidation and inflammation

Related subjects:

Molecular biology,

Basic medical science,

Basic medical science, other,

Clinical medicine,

Internal medicine,

Endocrinology, diabetology

© 2021 Douglas Edward Barre, Kazimiera Amelia Mizier-Barre, published by Slovak Academy of Sciences, Institute of Experimental Endocrinology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 55 (2021): Issue 3 (July 2021)